论文部分内容阅读
目前,在高血压的治疗中,血管紧张素Ⅱ受体(AT_1)拮抗剂成为继血管紧张素转化酶抑制剂(ACEI)之后新的一类受到临床医师关注的药物。新加坡国立大学医院心脏科的Boon-Lock Chia教授称这类AT_1拮抗剂代表着高血压治疗的一个新的里程碑。
At present, angiotensin II receptor (AT_1) antagonists become a new class of drugs of concern to clinicians after angiotensin converting enzyme inhibitor (ACEI) in the treatment of hypertension. Professor Boon-Lock Chia, from the cardiology department of the National University Hospital of Singapore, said such AT1 antagonists represent a new milestone in the treatment of hypertension.